The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use

Digestive and Liver Disease

Volumn 48, Issue 4, 2016, Pages 385-390

  Lim, Sun Gyo ^a   Park, Rae Woong ^a   Shin, Sung Jae ^a   Yoon, Dukyong ^a   Kang, Joon Koo ^a   Hwang, Jae Chul ^a   Kim, Soon Sun ^a   Kim, Jin Hong ^a   Lee, Kee Myung ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Clarithromycin; Drug resistance; Helicobacter pylori; Macrolides; Microbial

Indexed keywords

AMOXICILLIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; MACROLIDE; METRONIDAZOLE; PANTOPRAZOLE; QUINOLONE; RABEPRAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT; BISMUTH; LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT DURATION; UREA BREATH TEST; AGED; ANTIBIOTIC RESISTANCE; BREATH ANALYSIS; DRUG EFFECTS; HELICOBACTER INFECTIONS; MIDDLE AGED; RETROSPECTIVE STUDY; SOUTH KOREA; STATISTICAL MODEL; TEACHING HOSPITAL; TERTIARY CARE CENTER;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BISMUTH; BREATH TESTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITALS, TEACHING; HUMANS; LEVOFLOXACIN; LOGISTIC MODELS; MACROLIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84960803090     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.12.001     Document Type: Article

References (37)

1. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53:1374-1384.
2. Kim J.J., Reddy R., Lee M., et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. Journal of Antimicrobial Chemotherapy 2001, 47:459-461.
3. Eun C.S., Han D.S., Park J.Y., et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. Journal of Gastroenterology 2003, 38:436-441.
4. Wermeille J., Cunningham M., Dederding J.P., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause?. Gastroenterologie Clinique et Biologique 2002, 26:216-219.
5. Graham D.Y., Lew G.M., Malaty H.M., et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992, 102:493-496.
6. Miendje Deyi V.Y., Bontems P., Vanderpas J., et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. Journal of Clinical Microbiology 2011, 49:2200-2209.
7. Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Alimentary Pharmacology and Therapeutics 2007, 26:343-357.
8. Lee J.H., Sung I.-K., Kim J.H., et al. Impact of clarithromycin resistance on the outcome of standard triple Helicobacter pylori eradication therapy. Korean Journal of Helicobacter and Upper Gastrointestinal Research 2010, 10:14-20.
9. Noguchi N., Rimbara E., Kato A., et al. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. Journal of Medical Microbiology 2007, 56:1174-1180.
10. Nilsson H.O., Taneera J., Castedal M., et al. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. Journal of Clinical Microbiology 2000, 38:1072-1076.
11. Park I., Sheen S.S., Lim H.S., et al. Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database. American Journal of Cardiovascular Drugs 2012, 12:255-262.
12. Park M.Y., Yoon D., Choi N.K., et al. Construction of an open-access QT database for detecting the proarrhythmia potential of marketed drugs: ECG-ViEW. Clinical Pharmacology and Therapeutics 2012, 92:393-396.
13. Sheen S.S., Choi J.E., Park R.W., et al. Overdose rate of drugs requiring renal dose adjustment: data analysis of 4 years prescriptions at a tertiary teaching hospital. Journal of General Internal Medicine 2008, 23:423-428.
14. Yoon D., Park M.Y., Choi N.K., et al. Detection of adverse drug reaction signals using an electronic health records database: comparison of the laboratory extreme abnormality ratio (CLEAR) algorithm. Clinical Pharmacology and Therapeutics 2012, 91:467-474.
15. Park I.W., Sheen S.S., Yoon D., et al. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?. Journal of Clinical Pharmacy and Therapeutics 2014, 39:61-68.
16. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
17. Asaka M., Kato M., Takahashi S., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010, 15:1-20.
18. Kim S.G., Jung H.K., Lee H.L., et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Journal of Gastroenterology and Hepatology 2014, 29:1371-1386.
19. Goh K.L., Chan W.K., Shiota S., et al. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011, 16(Suppl. 1):1-9.
20. Kim J.M., Kim J.S., Jung H.C., et al. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean Journal of Gastroenterology 2004, 44:126-135.
21. Sung H., Chung H.J., Kim M.N., et al. Clinical usefulness of antimicrobial susceptibility test for Helicobacter pylori. Korean Journal of Laboratory Medicine 2006, 26:179-184.
22. Kim J.M., Kim J.S., Jung H.C., et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrobial Agents and Chemotherapy 2004, 48:4843-4847.
23. Lee J.W., Kim N., Kim J.M., et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013, 18:206-214.
24. Federico A., Nardone G., Gravina A.G., et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012, 143:55-61.
25. Romano M., Cuomo A., Gravina A.G., et al. Empiric levofloxacin-containing vs clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial. Gut 2010, 59:1465-1470.
26. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62:34-42.
27. Mamori S., Higashida A., Kawara F., et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. World Journal of Gastroenterology 2010, 16:4176-4179.
28. Agudo S., Perez-Perez G., Alarcon T., et al. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. Journal of Clinical Microbiology 2010, 48:3703-3707.
29. Glupczynski Y., Megraud F., Lopez-Brea M., et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. European Journal of Clinical Microbiology and Infectious Diseases 2001, 20:820-823.
30. Wolle K., Leodolter A., Malfertheiner P., et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. Journal of Medical Microbiology 2002, 51:705-709.
31. McMahon B.J., Hennessy T.W., Bensler J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Annals of Internal Medicine 2003, 139:463-469.
32. Zullo A., Perna F., Hassan C., et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Alimentary Pharmacology and Therapeutics 2007, 25:1429-1434.
33. Parsons H.K., Carter M.J., Sanders D.S., et al. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Alimentary Pharmacology and Therapeutics 2001, 15:1473-1478.
34. Prazeres Magalhaes P., De Magalhaes Queiroz D.M., Campos Barbosa D.V., et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrobial Agents and Chemotherapy 2002, 46:2021-2023.
35. Wong W.M., Xiao S.D., Hu P.J., et al. Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. Alimentary Pharmacology and Therapeutics 2005, 21:73-81.
36. Chung S.J., Lee D.H., Kim N., et al. Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease. Hepato-Gastroenterology 2007, 54:1293-1296.
37. Broutet N., Tchamgoue S., Pereira E., et al. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Alimentary Pharmacology and Therapeutics 2003, 17:99-109.